Advertisement

Journal of Clinical Immunology

, Volume 34, Supplement 1, pp 74–79 | Cite as

Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease

  • Norman RelkinEmail author
Article

Abstract

The human polyclonal IgG antibody preparation known as Intravenous Immunoglobulin (IVIG) has been under study as a potential treatment for Alzheimer’s disease (AD) since 2002. Preclinical and clinical studies have shown that IVIG has anti-amyloid and immune modulatory properties relevant to treating neurodegenerative disorders. In early stage AD clinical trials, IVIG was found to reduce cognitive decline and increase brain glucose metabolism. Unfortunately, IVIG failed to meet primary outcome objectives in the North American Phase 3 clinical trial in mild to moderate AD. However, positive cognitive signals were observed in pre-planned subgroup analyses among APOE-ε4 carriers and moderately impaired AD patients. Biomarker studies revealed dose dependent increases in plasma and CSF immunoglobulins and decreases in beta amyloid-42 levels. In addition, IVIG treatment was generally safe and well-tolerated. These findings suggest that naturally occurring human anti-amyloid antibodies may play a physiologic role in the clearance of aggregated amyloid proteins. While the results of clinical trials to date do not provide support for the use of IVIG to treat AD at the doses tested, additional studies of IVIG’s mechanisms are warranted and may guide the development of more effective therapies for AD in the future.

Keywords

Human intravenous immunoglobulin polyclonal IgG alzheimer’s disease beta amyloid immunotherapy clinical trials 

Notes

Acknowledgments

The author acknowledges the support of the National Institute on Aging through a grant to the Alzheimer’s disease Cooperative Study Group and Baxter for its support of all phases of the US studies of IVIG for Alzheimer’s.

References

  1. 1.
    Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12(10):383–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Schenk D et al. Immunization with amyloid-beta attenuates Alzheimer- disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev. 2012;11(11):792–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Gaskin F, Finley J, Fang Q, et al. Human antibodies reactive with beta-amyloid protein in Alzheimer’s disease. J Exp Med. 1993;177:1181–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57:801–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann Neurol. 2001;49:808–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer’s disease. Ann Neurol. 2002;52:253–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Szabo P, Mujalli DM, Rotondi ML, et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol. 2010;227:167–74.PubMedCrossRefGoogle Scholar
  13. 13.
    O’Nuallain B, Williams AD, McWilliams-Koeppen HP, et al. Anti-amyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol. 2010;30 Suppl 1:S37–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Ferreira ST, Klein WL. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol Learn Mem. 2011;96(4):529–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Enciu A, Popescu BO. Is there a causal link between inflammation and dementia? Biomed Res Int. 2013:ID: 316495. 1–6.Google Scholar
  16. 16.
    Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009;30:1728–36.PubMedCrossRefGoogle Scholar
  17. 17.
    Puli L, Pomeshchik Y, Olas K, et al. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease. J Neuroinflammation. 2012;9:105.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2004;75:1472–4.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Tsakanikas D, Relkin N. Neuropsychological outcomes following 18-months of uninterrupted intravenous immunoglobulin (IGIV) treatment in patients with Alzheimer’s disease. Toronto: American Academy of Neurology; 2010.Google Scholar
  20. 20.
    Devi G, Schultz S, Khosrowshahi L, et al. A retrospective chart review of the tolerability and efficacy of intravenous immunoglobulin in the treatment of Alzheimer’s disease. J Am Geriatr Soc. 2008;56:772–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013;12:233–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Relkin N, on behalf of the GAP Sttudy Group. Results of GAP (160701): a phase III study of intravenous gammaglobulin for the treatment of mild to moderate Alzheimer’s disease. Presented at AAIC, Boston 2013.Google Scholar
  23. 23.
    Fillit H, Hess G, Hill J, et al. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology. 2009;73(3):180–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Neurology and Brain Mind Research InstituteWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations